Although the clinical utility of Wnt7a is very limited due to the unavailability of clinically suitable recombinant Wnt7a protein, our identification of Iloprost, a prostacyclin analog and a Wnt7a mimic, as a novel regulator of cellular senescence opens new opportunities for utilizing pro-senescence therapy in lung cancers. This evidence concerns the gene WNT7A and lung carcinoma.